VTCN1/B7-H4
Alpha Lifetech can provide VTCN1/B7-H4 corresponding products, help each customer's research and development.
01
Introduction To VTCN1/B7-H4
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to VTCN1/B7-H4 domain is a common target in medicine.
B7-H4 is one of the important members of the B7 family, also known as B7S1 or VTCN 1. It is a type I transmembrane protein containing 282 amino acids and consists of a signal peptide region, an extracellular region composed of the IgV and IgC domains, a transmembrane region, and an intracellular region. B7-H4 (VTCN 1), a molecule highly expressed in tumor cells and placental trophoblast cells, exhibits striking similarities in its expression patterns in two distinct biological contexts. Human B7-H4 mRNA is widely expressed in normal tissues, but the expression of the B7-H4 protein is tightly controlled. To date, the receptors for B7-H4 remain unknown. Several studies have shown that B7-H4 is overexpressed in a variety of tumor cells (especially ovarian, biliary epithelial, breast, and endometrial), antigen-presenting cells, and tumor-associated macrophages.
Function of Target VTCN1/B7-H4
B7-H4 is overexpressed in a variety of tumor cells (especially ovarian cancer, bile duct epithelial cancer, breast cancer, and endometrial cancer), antigen-presenting cells, and tumor-related macrophages, which plays a negative synergistic costimulatory molecule and plays an important role in the occurrence and immunity of cancer. B7-H4 can promote tumor progression by enhancing the proliferation, invasion, metastasis, and antiapoptotic capacity of tumor cells by participating in various cell signal transduction pathways. Inhibit T cell proliferation, inhibit the activation of T cells, inhibit the humoral immune response, regulate innate immune sensing, and participate in the inflammatory response. Suppresses the T-cell response to β -cells, thus preventing β -cell destruction.
Gene Pathway of Target VTCN1/B7-H4
Progesterone, a female sex hormone critical for pregnancy, has been identified as a key driver of B7-H4 expression in placental carcinoma and breast cancer cells. This axis involves the recruitment of the histone acetyltransferase P300 and the epigenetic reader BRD 4, which together coordinate B7-H4 expression in response to progesterone signaling. Progesterone receptor binds to the newly identified 58 kb enhancer, thus mediating B7-H4 transcription via the PR-P300-BRD 4 axis. B7-H4 expression suppresses doxorubicin-induced cell death by inhibiting calreticulin exposure relative to eIF2α phosphorylation required by cancer cells. Inhibition of B7-H4 glycosylation by NGI-1 leads to its ubiquitination and subsequent degradation, improved immunogenicity of cancer cells treated with doxorubicin, and enhances phagocytosis of dendritic cells and their ability to initiate CD8IFNγ -producing T cell responses.
Fig 1: B7-H4 Gene Pathway. (Reference source: Wang JY, Wang WP. B7-H4, a promising target for immunotherapy. Cell Immunol. 2020 Jan;347:104008. )
Alpha Lifetech Can Provide
Currently, various immune drugs targeting VTCN1/B7-H4 targets are in the updating iteration, and taking the disease alone or in combination with other products has become a new approach with remarkable achievements. The VTCN1/B7-H4 targets have shown important research value and application prospects in both biology and drug research and development. With further research and detection technology advances, VTCN1/B7-H4 target products are also essential in medical research. Alpha Lifetech can provide VTCN1/B7-H4 corresponding products and help each customer's research and development. Alpha Lifetech provides end-to-end biotechnology development solutions, from upstream cell culture optimization to downstream purification scale. Our process is validated through analytical techniques such as HPLC, SDS-PAGE, and mass spectrometry to ensure product consistency and regulatory compliance. By combining cutting-edge biotechnology expertise with flexible service models, we help clients accelerate project research progress and ensure smooth experimentation.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64594 | 50ug,100ug,500ug | |
| ALP64563 | 50ug,100ug,500ug | |
| ADT1025 | 100ug,1mg,5mg | |
Reference
[1] Wang JY, Wang WP. B7-H4, a promising target for immunotherapy. Cell Immunol. 2020 Jan;347:104008.
[2] Yu J, Yan Y, Li S, Xu Y, Parolia A, Rizvi S, Wang W, Zhai Y, Xiao R, Li X, Liao P, Zhou J, Okla K, Lin H, Lin X, Grove S, Wei S, Vatan L, Hu J, Szumilo J, Kotarski J, Freeman ZT, Skala S, Wicha M, Cho KR, Chinnaiyan AM, Schon S, Wen F, Kryczek I, Wang S, Chen L, Zou W. Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance. Cell. 2024 Jun 28:S0092-8674(24)00652-4.
[3] Song X, Zhou Z, Li H, Xue Y, Lu X, Bahar I, Kepp O, Hung MC, Kroemer G, Wan Y. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers. Cancer Discov. 2020 Dec;10(12):1872-1893.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102